PALO ALTO, Calif.- January 6, 2020—Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced today that senior executives will be speaking at two healthcare innovation and investor conferences in San Francisco. ● Brent Vaughan, CEO and co-founder of Cognoa, will provide an update on the company’s milestones and strategy at the Digital Medicine & Medtech Showcase™ 2020,…
Cognoa launches a pivotal study to demonstrate the effectiveness of its diagnostic aid for autism spectrum disorder (ASD). Read article here.
Mosbrooker will be leading the operational and commercial efforts of Cognoa’s digital behavioral health products (Palo Alto, Calif. – January 14, 2021) – Cognoa, the leading pediatric behavioral health company developing diagnostic and therapeutic solutions for children living with autism and other behavioral health conditions, today announced the appointment of Eric B. Mosbrooker as Chief Operations Officer. Mosbrooker will be…
Written By Jason Hartman As a part of our series about business leaders who are shaking things up in their industry, I had the pleasure of interviewing David Happel. David Happel is the President and CEO of Cognoa, the leading digital diagnostics and therapeutics company developing FDA cleared pediatric behavioral health solutions. Prior to joining Cognoa, Happel served as President,…
by Katie Cloyd – December 18, 2020 So, you think your young child might be on the autism spectrum. Maybe they’re not talking or communicating as expected, or they don’t seem to understand when you talk to them. Perhaps they seem exceptionally frustrated and their tantrum behaviors don’t seem developmentally typical to you. Like many other parents, I have been there. My son was…
Graison Dangor Contributor Healthcare I cover the intersection of mental health, the economy, and policy. A tool that helps pediatricians diagnose autism with artificial intelligence and smartphone video passed a key FDA test and could hit the market as soon as next summer, according to device-maker Cognoa, which recently announced its plans to submit the tool for final approval. In…
Single parents often carry the pressures of parenting on their own and burnout comes hard and fast. Relief does exist in the form of a support village—here’s what to know and how to create yours. By Adrienne Farr Parenting is tough. Worrying about finances, household chores, morning and bedtime routines, child-friendly recreation, doctor’s visits and everything in between can feel unbearable—for…
By Meg Bryant Children with autism spectrum disorder (ASD) can face a lifetime of frustration because of challenges with communication, social behaviors and flexibility of thought. Early intervention can improve outcomes, but nailing a diagnosis of ASD often takes years. Cognoa Inc. wants to change that with its digital ASD Diagnostic and is on track to apply for U.S. FDA clearance before the…
US firm Cognoa is targeting FDA approval for its AI-based smartphone app – which aims to improve the current approach to diagnosing autism in children By Jamie Bell A new digital method for diagnosing autism in children may be set for FDA clearance after demonstrating “unparalleled accuracy” in a real-world study. Cognoa — a California-based paediatric behavioural health company — has…
by Conor Hale Cognoa aims to equip primary care pediatricians with an artificial-intelligence-powered digital app that can spot the signs of autism, allowing them to rule out or diagnose spectrum disorders within the doctor’s office or remotely. This could represent a broad shift in the standard of care, as most children are referred to specialists for diagnosis and later treatment—a process…
The startup Cognoa has submitted its app-based tool for FDA clearance By Megan Scudellari This week, a California-based company announced it will seek FDA clearance for a first-of-its-kind autism spectrum disorder (ASD) diagnostic tool. Cognoa’s technology uses artificial intelligence to make an ASD diagnosis within weeks of signs of concern—far faster than the current standard of care. If cleared by the FDA, it would be…
Cognoa’s autism diagnostic device is positioned to be the first FDA-cleared digital solution enabling pediatricians to diagnose autism – a paradigm shift in the standard of care (Palo Alto, Calif. – September 23, 2020) – Cognoa, the leading pediatric behavioral health company developing diagnostic and therapeutic solutions for children living with autism and other behavioral health conditions, announced today that…
